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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Slovak language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 108 JIA patients (5.6% systemic, 38.9% oligoarticular, 30.5% RF-negative polyarthritis, 
25% other categories) and 100 healthy children were enrolled in two centres. Notably, none of the enrolled JIA patients is 
affected with psoriatic arthritis. The JAMAR components discriminated healthy subjects from JIA patients. All JAMAR 
components revealed good psychometric performances. In conclusion, the Slovak version of the JAMAR is a valid tool for 
the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Slovak parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthri-
tis (JIA). The JAMAR assesses the most relevant parent/
patient-reported outcomes in JIA, including overall well-
being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with ill-
ness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Slovak language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from October 2011 
to December 2012. Children were recruited after Ethics 
Committee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, and 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF -HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to the international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e. Spanish in South Ameri-
can countries), only the probe technique was performed. 
Reading comprehension and understanding of the translated 
questionnaires were tested in a probe sample of 10 JIA par-
ents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
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JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal items–scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Slovak parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Slovak JAMAR was fully cross-culturally adapted from 
the standard English version with two forward and two back-
ward translations with a concordance for 118/123 transla-
tions lines (95.9%) for the parent version and 118/120 lines 
(98.3%) for the child version.
In the probe technique analysis, 121/123 (98.4%) lines 
of the parent version of the JAMAR were understood by 
at least 80% of the 10 parents tested (median 100%; range 
50–100%). Lines 114 and 115 were modified according to 
parents indications; 118/120 (98.3%) lines of the patient ver-
sion of the JAMAR were understood by at least 80% of the 
children (median 100%; range 70–100%). Lines 55 and 62 
were modified according to patients indications.
Demographic and clinical characteristics 
of the subjects
A total of 108 JIA patients and 100 healthy children (total 
of 208 subjects) were enrolled at two paediatric rheumatol-
ogy centres.
In the 108 JIA subjects, the JIA categories were 5.6% 
with systemic arthritis, 38.9% with oligoarthritis, 30.5% 
with RF-negative polyarthritis, 3.7% with RF-positive pol-
yarthritis, 13% with enthesitis-related arthritis and 8.3% 
with undifferentiated arthritis (Table 1). Notably, none of 
the enrolled JIA patients is affected with psoriatic arthritis.
A total of 203/208 (97.6%) subjects had the parent ver-
sion of the JAMAR completed by a parent (104 from parents 
of JIA patients and 99 from parents of healthy children). The 
JAMAR was completed by 167/203 (82.3%) mothers and 
36/203 (17.7%) fathers. The child version of the JAMAR 
was completed by 175/208 (84.1%) children age 6.1 or older. 
Also patients younger than 7 years old, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. Results refer 
mainly to the parent’s version findings, unless otherwise 
specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for items 1, 2 and 6, whereas a reduced number of 
response choices were used for all the PF items except for 
items 3, 4, 5 and 10.
The mean and SD of the items within a scale were roughly 
equivalent for the PF and for the HRQoL items, except for 
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Table 1  Descriptive statistics (medians 1st–3rd quartiles or absolute frequencies and %) for the 108 JIA patients.
Data related to the JAMAR refer to the 104 JIA patients and to the 99 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Systemic Oligoarthritis RF − poly-
arthritis
RF + poly-
arthritis
Enthesitis-
related arthritis
Undifferenti-
ated arthritis
All JIA patients Healthy
N = 6 N = 42 N = 33 N = 4 N = 14 N = 9 N = 108 N = 100
Female 2 (33.3%) 29 (69%) 25 (75.8%) 4 (100%) 1 (7.1%) 6 (66.7%) 67 (62%)* 50 (50%)
Age at visit 8.4 (4.2–10.2) 10.4 (6.9–17.2) 17.1 (10.3–18) 16.2 (15.2–
16.9)
15.5 (14.3–
17.3)
10.1 (6.9–11.1) 12.8 (8.5–
17.3)*
13.1 (10.1–16)
Age at onset 2.5 (1.9–9.3) 6 (2.8–10.3) 9.4 (2.5–13.6) 15 (13.2–15.6) 12 (10.1–13.6) 9.4 (4.7–9.9) 9.1 (3–12.1)*
Disease duration 2.1 (0.9–6) 3.9 (1.5–5.2) 4.1 (2.4–8.4) 1.6 (0.6–2.6) 3.8 (1.8–4.6) 0.7 (0.3–1.9) 3.4 (1.4–6.1)*
ESR 15 (9–25) 6 (5–10) 5 (3–10) 5 (4–10) 5 (4–14) 12 (11–13) 6 (4–11)
MD VAS 0 (0–3) 0 (0–3) 1.5 (0–4) 1.5 (0–3.5) 0 (0–1) 2 (1–4) 0 (0–4)
No. of swollen 
joints
0 (0–2) 0 (0–1) 0 (0–2) 1 (0–2) 0 (0–0) 1 (0–2) 0 (0–1)
No. of joints with 
pain
1 (0–3) 0 (0–1) 1 (0–3) 0 (0–1) 0.5 (0–3) 0 (0–1) 0 (0–2)
No. of joints with 
LOM
0 (0–4) 0 (0–1) 1 (0–2) 1.5 (0.5–2) 0 (0–1) 0 (0–1) 0 (0–1)
No. of active 
joints
0 (0–2) 0 (0–1) 1 (0–2) 1 (0–2) 0 (0–1) 1 (0–2) 0 (0–2)
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 13 (31%) 13 (39.4%) 1 (25%) 1 (7.1%) 0 (0%) 28 (25.9%)*
Uveitis 0 (0%) 3/38 (7.9%) 2 (6.1%) 0 (0%) 1 (7.1%) 1 (11.1%) 7/104 (6.7%)
PF total score 2.5 (0–6) 0 (0–2) 5 (2–8) 0 (0–0.5) 1.5 (0–5.5) 1 (0–4) 1.5 (0–5)* 0 (0–0)#
Pain VAS 2.3 (0–3.5) 0.8 (0–3) 2.5 (1–3.5) 1.8 (1.3–2.8) 2.3 (0–3.8) 2 (0.5–3) 2 (0–3.3) 0 (0–0)#
Disease activity 
VAS
1.3 (0–3.5) 0.8 (0–3.5) 2 (0.5–3.5) 1.3 (0.8–2) 2.3 (0–4.3) 2.5 (0.5–3) 1.5 (0–3.5)
Well-being VAS 1.3 (0–3.5) 0.5 (0–2) 2 (0.5–4) 1.8 (0.8–2.8) 1.5 (0.5–5) 0.5 (0–0.5) 1 (0–3.3)
HRQoL-PhH 3.5 (1–8) 1 (0–3) 3 (2–4) 1.5 (0.5–2.5) 3.5 (1.5–5.5) 1 (1–2) 2 (1–4)* 0 (0–0)#
HRQoL-PsH 2 (1–6) 0 (0–3) 3 (1–5) 0.5 (0–1) 2 (1.5–5.5) 1 (1–2) 2 (0–3.5)* 1 (0–2)*
HRQoL total 
score
8.5 (2–99) 2 (0.5–5) 6 (3–10) 2 (1–3) 5 (3.5–11) 3 (2–4) 4 (2–8)* 1 (0–3)#
Pain/swell. in > 1 
joint
3 (50%) 19/40 (47.5%) 28 (84.8%) 2 (50%) 7/12 (58.3%) 6 (66.7%) 65/104 (62.5%) 3/99 (3%)#
Morning stiff-
ness > 15 min
3 (50%) 7/40 (17.5%) 10 (30.3%) 2 (50%) 1/12 (8.3%) 0 (0%) 23/104 (22.1%) 0 (0%)#
Subjective remis-
sion
2 (33.3%) 17/40 (42.5%) 25 (75.8%) 2 (50%) 9/12 (75%) 7 (77.8%) 62/104 
(59.6%)*
In treatment 6 (100%) 33/40 (82.5%) 31 (93.9%) 4 (100%) 12/12 (100%) 8 (88.9%) 94/104 (90.4%)
Reporting side 
effects
2 (33.3%) 6/33 (18.2%) 12/31 (38.7%) 0 (0%) 2/12 (16.7%) 2/8 (25%) 24/94 (25.5%)
Taking medica-
tion regularly
6 (100%) 33/33 (100%) 31/31 (100%) 4 (100%) 11/12 (91.7%) 7/8 (87.5%) 92/94 (97.9%)*
With problems 
attending 
school
0 (0%) 1/22 (4.5%) 3/12 (25%) 0 (0%) 1/6 (16.7%) 0 (0%) 5/49 (10.2%) 0 (0%)*
Satisfied with dis-
ease outcome
3 (50%) 24/40 (60%) 12 (36.4%) 3 (75%) 6/12 (50%) 4 (44.4%) 52/104 (50%)
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HRQoL items 1 and 5 (data not shown). The median number 
of items marked as not applicable was 0% (0–1%) for the PF 
and 3.5% (1–8%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 83.7% (77.9–93.3%) for the 
PF items, 53.8% (39.4–71.2%) for the HRQoL PhH items, 
and 56.7% (52.9–66.3%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0–1%) for the PF items, 
1.9% (0–2.9%) for the HRQoL PhH items, and 1.9% 
(0–2.9%) for the HRQoL PsH items. The median floor 
effect was 27.9% for the pain VAS, 26% for the disease 
activity VAS and 29.8% for the well-being VAS. The 
median ceiling effect was 0% for the pain VAS, 1% for 
the disease activity VAS and 0% for the well-being VAS.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent, N = 104/203 Child N = 78/175
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 83.7% 91.0%
 HRQoL PhH 53.8% 66.7%
 HRQoL PsH 56.7% 69.2%
 Pain VAS 27.9% 25.6%
 Disease activity VAS 26.0% 29.5%
 Well-being VAS 29.8% 28.2%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 1.9% 2.6%
 HRQoL PsH 1.9% 1.3%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 1.0% 1.3%
 Well-being VAS 0.0% 0.0%
Items with equivalent item–scale correlation 100% for PF, 100% for HRQoL 100% for PF, 90% for HRQoL
Items with item–scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 87% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.83 0.84
 PF-HW 0.90 0.89
 PF-US 0.83 0.68
 HRQoL-PhH 0.82 0.81
HRQoL-PsH 0.84 0.78
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.98 0.89
 HRQoL-PhH 0.76 0.98
 HRQoL-PsH 0.93 0.84
Spearman correlation with JIA core set variables, median
 PF 0.5 0.6
 HRQoL PhH 0.6 0.6
 HRQoL PsH 0.3 0.2
 Pain VAS 0.5 0.3
 Disease activity VAS 0.5 0.3
 Well-being VAS 0.5 0.4
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Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 100% of the 
PF items and for 100% of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.83 for PF-LL, 0.90 for PF-HW, 
and 0.83 for PF-US. Cronbach’s alpha was 0.82 for 
HRQoL-PhH and 0.84 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 11 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 8 days (range 6–15 days). The intraclass 
correlation coefficients (ICC) for the PF total score showed 
an almost perfect reproducibility (ICC = 0.98). The ICC 
for the HRQoL PhH showed a substantial reproducibility 
(ICC = 0.76) while the ICC for the HRQoL PsH showed 
an almost perfect reproducibility (ICC = 0.93).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.6 
(median = 0.5). The PF total score best correlation was 
observed with the parent global assessment of well-being 
(r = 0.6, p < 0.001). For the HRQoL, the median correla-
tion of the PhH with the JIA core set of outcome vari-
ables ranged from 0.4 to 0.7 (median = 0.6), whereas for 
the PsH ranged from 0.2 to 0.4 (median = 0.3). The PhH 
and the PsH showed the best correlation with the par-
ent global assessment of well-being (r = 0.7, p < 0.001 
and r = 0.5, p < 0.001, respectively). The median corre-
lations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centred and 
laboratory measures were 0.5 (0.3–0.6), 0.5 (0.4–0.6), 0.5 
(0.3–0.6), respectively.
Discussion
In this study, the Slovak version of the JAMAR was cross-
culturally adapted from the original standard English version 
with two forward and two backward translations. According 
to the results of the validation analysis, the Slovak parent 
and patient versions of the JAMAR possess satisfactory psy-
chometric properties. The disease-specific components of 
the questionnaire discriminated well between patients with 
JIA and healthy controls. The PF total score proved to dis-
criminate between the different JIA subtypes with children 
with RF-negative poly-arthritis having a higher degree of 
disability. The HRQoL total score also proved to discrimi-
nate between the different JIA subtypes with children with 
systemic arthritis having a lower health-related quality of 
life.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was good 
for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Slovak version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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